1. Home
  2. TENB vs ADPT Comparison

TENB vs ADPT Comparison

Compare TENB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$17.92

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.76

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENB
ADPT
Founded
2002
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
TENB
ADPT
Price
$17.92
$14.76
Analyst Decision
Buy
Strong Buy
Analyst Count
18
9
Target Price
$32.76
$17.78
AVG Volume (30 Days)
2.4M
2.2M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
3.23
63.89
EPS
N/A
N/A
Revenue
$999,405,000.00
$276,976,000.00
Revenue This Year
$9.37
$3.98
Revenue Next Year
$7.04
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
11.04
54.77
52 Week Low
$15.85
$6.77
52 Week High
$35.69
$20.76

Technical Indicators

Market Signals
Indicator
TENB
ADPT
Relative Strength Index (RSI) 41.27 53.20
Support Level $17.28 $12.19
Resistance Level $21.25 $17.52
Average True Range (ATR) 1.00 0.80
MACD 0.01 0.21
Stochastic Oscillator 42.12 75.99

Price Performance

Historical Comparison
TENB
ADPT

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: